Carvykti’s T2V Receives an RSI; When Could Abecma and Carvykti Receive a CHMP Positive Opinion? September CHMP Highlights
Here is a brief preview of this blast: On Friday, September 15, the CHMP meeting highlights were released. Of note, Carvykti (JNJ / Legend’s BCMA CAR-T) was absent from the CHMP highlights implying that it has received a Request for Supplementary Information (RSI) for its assessment in ≥2L MM. Moreover, recall that Abecma (BMS / 2seventy’s BCMA CAR-T) was not included on Monday’s CHMP agenda. Below, Celltelligence provides insights on the September CHMP meeting with updated EU regulatory timelines for both cell therapies.